UNSPSC 51101639: Clamoxyquin

This classification denotes an antiprotozoal agent with the molecular formula C17H24ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier JUN13FZ6RF, chemically known as cn-17,900-2b but generally known as clamoxyquin, which bears US NIH Compound Identifier 18029. European Medicines Agency schedules Clamoxyquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06637MIG.

The term CLAMOXYQUINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 21 No. 12 1967, List 7). As of Q4 2014, CLAMOXYQUIN remains the US FDA Preferred Term for this commodity. Clamoxyquin bears US NLM identifiers UMLS ID C2699337 and NCI Concept Code C78097. SMILES: CCN(CC)CCCNCC1=CC(=C2C=CC=NC2=C1O)CL.

UNSPSC 51101639 Clamoxyquin is a Commodity code that in practice covers pharmaceutical products and medical supplies procured by state and local health departments, emergency services, and cooperative purchasing alliances for community health, first-response, and employee benefit programs. Recent solicitations under this code span naloxone and drug deactivation systems for county public health initiatives, emergency medical and first aid supplies for fire department rescue operations, generic pharmaceuticals and over-the-counter products distributed through state cooperative purchasing networks, and direct-to-manufacturer pharmacy benefit programs. The issuing bodies include county health departments, municipal fire departments, state health and human services commissions, and multistate cooperative purchasing alliances. Work ranges from procurement of discrete emergency-response medical supplies in modest quantities to large-scale generic pharmaceutical contracting across multiple jurisdictions through established wholesaler channels.

Activity is geographically dispersed across Florida, Texas, Minnesota, and Oregon, with representation from county-level health and emergency services, standalone city procurement offices, state health agencies, and regional cooperative purchasing vehicles. Representative recent opportunities include Seminole County, Florida's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually (due Jul 26, 2023), the City of Tampa's IFB for 169 line items of emergency medical supplies for its Fire Department Rescue Division with an estimated contract value of $700,000 and a Small Local Business Enterprise set-aside at 5% discount (due Mar 13, 2026), the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products across state and local facilities effective July 1, 2026 (due Mar 26, 2026), and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription fulfillment capabilities (due Apr 3, 2026). Cooperative purchasing vehicles and state agencies appear as active repeat buyers for pharmaceutical and OTC product lines.